Clinical trials: Heart Failure with Preserved Ejection Fraction
Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction
Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study
This study is designed to evaluate the safety, feasibility, and effectiveness of a 12-week eccentric exercise program for older adults with sarcopenia (muscle loss) or sarcopenic obesity and chronic heart failure (HF).
- Conditions
- Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction, Sarcopenia in Elderly, Sarcopenic Obesity
- Trial name
- ECLYPSE-HF (NCT06826963)
- Testing
- Aerobic eccentric intervention
- Where
- 2 sites in Italy
- Volunteers
- 15 people
- Sponsor
- Universita di Verona
HF - Heart Failure, Diabetes Mellitus
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
This is a single-center, non-randomzied pilot study investigating a combination of targeted therapies as possible treatment for heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT04697485
- Testing
- Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
- Where
- United States
- Sponsor
- Northwestern University
Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
The main objective of this study is to assess the hemodynamic effects of sacubitril-valsartan in patients with heart failure with preserved ejection fraction and at least moderate atrial functional mitral regurgitation (AFMR)…
- Trial name
- PRAISE-MR (NCT05991284)
- Testing
- Sacubitril-valsartan, Standard of care
- Where
- Belgium
- Volunteers
- 84 people
- Sponsor
- Ziekenhuis Oost-Limburg
Heart Failure With Preserved Ejection Fraction
The COLchicine HEART Failure PRESERVED Trial (COLHEART-PRESERVED)
The purpose of this study is to investigate the effects of colchicine on heart failure related health status, quality of life, and vascular and cardiac function in patients with heart failure with preserved ejection fraction…
- Trial name
- NCT06081049
- Testing
- Colchicine
- Where
- Denmark
- Volunteers
- 152 people
- Sponsor
- Tor Biering-Sørensen
Heart Failure With Preserved Ejection Fraction (HFPEF)
Association of Heterogeneous Circulating Biomarkers and Anamnestic Factors of Pregnancy Adverse Course and Outcomes With the Prognosis of Heart Failure With Preserved Ejection Fraction
The primary purpose of this study is to evaluate possible association of some heterogeneous circulating biomarkers and anamnestic factors of pregnancy adverse course and outcomes with the prognosis of heart failure with preserved…
- Trial name
- CARPO-HF (NCT06803849)
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure With Preserved Ejection Fraction (HFpEF), Atrial Fibrillation
Intracranial Pressure and a Potential Vicious Circle of Atrial Fibrillation in HFpEF
This study was designed to investigate predictors of atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF), with a particular focus on the potential relationship between venous…
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF), Atrial Fibrillation, Optic Nerve Sheath Diameter, Intracranial Pressure
- Trial name
- heart failure (NCT07521293)
- Testing
- Echocardiography
- Where
- Turkey (Türkiye)
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- Ankara Ataturk Sanatorium Training and Research Hospital
Heart Failure With Preserved Ejection Fraction, Hypertension
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a critical public health problem. Heart failure (HF) affects over 5 million adults in the United States (US), and is a major source of morbidity, mortality, and impaired…
- Trial name
- BLOCK HFpEF (NCT04434664)
- Testing
- Amlodipine Besylate, Metoprolol Succinate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Heart Failure With Preserved Ejection Fraction
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
The REHAB-HFpEF trial will determine whether a novel physical rehabilitation intervention will improve the primary outcome of combined all-cause rehospitalizations and mortality and the secondary outcome of major mobility…
- Trial name
- REHAB-HFpEF (NCT05525663)
- Testing
- Rehabilitation Intervention
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- Wake Forest University Health Sciences
Fontan Circulation, Single Ventricle Heart Disease
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT06762964
- Testing
- Dapagliflozin tablet
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Heart Failure, Systemic Inflammation
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks…
- Trial name
- ATHENA (NCT06200207)
- Testing
- Ziltivekimab
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 673 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF)
Optimised Cardiovascular and Renal Protection in Patients With Chronic Kidney Disease and Cardiovascular Disease
The goal of this clinical trial is to investigate whether care in a specialised Cardio-Renal Clinic can improve the health of people living with both cardiovascular disease and chronic kidney disease.
- Conditions
- Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF), Cardiovascular Diseases
- Trial name
- OPTICARE (NCT07835828)
- Testing
- Multidisciplinary Cardio-Renal Care
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- Odense University Hospital
Heart Failure With Preserved Ejection Fraction
3-Month Home-based Training With Whole Body Vibration (WBV) Device in Patients With Heart Failure and Preserved Ejection Fraction (GALILEO-HFpEF-HOME) (GALILEOHOME)
In order to evaluate Long-term effects of whole Body Vibration (wbv) in patients with HFpEF patients will get a training device to use at home for 3 months.
- Trial name
- GALILEO-HFpEF (NCT04239807)
- Testing
- Group 1 GALILEO WBV, Group 2 Control
- Volunteers
- 60 people
- Sponsor
- Klinikum der Universität Köln
Heart Failure
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease.
- Trial name
- NCT06809686
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Richmond Research Institute
Heart Failure
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more.
- Trial name
- NCT06424288
- Testing
- vicadrostat, empagliflozin
- Where
- 671 sites in United States, Argentina and 28 more
- Volunteers
- 6,712 people
- Sponsor
- Boehringer Ingelheim
Heart Failure With Preserved Ejection Fraction
CHIP in Endothelial Dysfunction Associated With HEpEF
This study aims at identifying processes that are deregulated in blood cells by Clonal Hematopoiesis of Indeterminate Potential (CHIP) which are involved in the development of heart failure with preserved ejection fraction…
- Trial name
- CHiEF (NCT05828888)
- Volunteers
- 80 people
- Sponsor
- University Hospital, Bordeaux
Heart Failure NYHA Class II, Heart Failure NYHA Class III
CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis
The study aims to test the diagnostic accuracy of T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that T1 mapping in older patients with symptomatic heart failure, increased LV wall thickness…
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure With Preserved Ejection Fraction
- Trial name
- CMR for CA (NCT04862273)
- Testing
- Native T1 CMR, Web-based ATTR probability estimator (Pfizer, New York), 99mTc-DPD scintigraphy
- Where
- Germany
- Volunteers
- 112 people
- Sponsor
- University of Leipzig
Heart Failure, Heart Failure, Diastolic
Data-Driven Phenotyping in Heart Failure With Preserved Ejection Fraction
The goal of this observational study is to learn how people with Heart Failure with Preserved Ejection Fraction (HFpEF) can be grouped into different "phenotypes" based on their clinical information.
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- NCT07429396
- Where
- 2 sites in Portugal
- Volunteers
- 200 people
- Sponsor
- Instituto Politécnico de Leiria